Juvenile absence epilepsy

Juvenile absence epilepsy (JAE) is a genetic generalized epilepsy syndrome that typically begins during adolescence, usually between the ages of 10 and 17 years, with a peak onset around 12 years of age. It is characterized by absence seizures — brief episodes of impaired consciousness during which the individual appears to stare blankly and becomes unresponsive to their surroundings, typically lasting 4 to 30 seconds. These absences are associated with generalized 3–4 Hz spike-and-wave discharges on electroencephalography (EEG). Unlike childhood absence epilepsy, the absence seizures in JAE tend to occur less frequently (often a few times per day rather than dozens) but are more likely to be accompanied by other seizure types. A distinguishing feature of JAE is the high frequency of associated generalized tonic-clonic seizures (GTCS), which occur in approximately 80% of patients, often upon awakening. Myoclonic jerks may also occur in a subset of individuals. The condition primarily affects the central nervous system, specifically involving abnormal neuronal excitability in cortical and thalamocortical circuits. Cognitive function is generally preserved, though some patients may experience subtle difficulties with attention and executive function. JAE is considered a lifelong condition in many cases, with seizures persisting into adulthood more frequently than in childhood absence epilepsy. Treatment is based on antiseizure medications, with valproate (valproic acid) being considered the most effective first-line therapy, particularly when generalized tonic-clonic seizures are also present. Lamotrigine and levetiracetam are alternative options, especially in females of childbearing potential due to the teratogenic risks of valproate. Ethosuximide may be used if only absence seizures are present. Carbamazepine and phenytoin should be avoided as they may worsen absence seizures. With appropriate treatment, many patients achieve good seizure control, though medication may need to be continued long-term.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Juvenile absence epilepsy